Description
S2212: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
This trial is available at multiple Sutter Locations. Please contact one of the following about S2212:
San Francisco: Sophia Vue ClinicalResearch@sutterhealth.org
Palo Alto/Santa Cruz: Tanya Pozniansky clinicaltrials@pamf.org
PAMF/Fremont: Tanya Pozniansky clinicaltrials@pamf.org
East Bay: Piante’ Berniard Piante.Berniard@sutterhealth.org
Sacramento: Kirsten Babski SIMR@sutterhealth.org
Modesto: Kirsten Babski SIMR@sutterhealth.org
Solano-Vallejo Cancer Center: Kirsten Babski
Principal Investigator
Related Studies
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: External PI, Principal Investigator, Xiaowei (Sherry) Yan, PhD, MS